

# 11<sup>th</sup> MILAN CONGRESS ON INNOVATIVE ANTICANCER THERAPY



Fondazione IRCCS  
Istituto Nazionale dei Tumori

Sistema Socio Sanitario

Regione  
Lombardia

## WEBINAR CONGRESS

21 January 2021 from 14.50 to 18.40

22 January 2021 from 15.30 to 18.00

# FAD

## RATIONALE

The 11th "Milan Congress on Innovative Anticancer Therapy" will present leading international experts in the field of immuno-oncology and cancer cell signaling to investigate the potentials, opportunities and challenges of immunotherapy and targeted therapies. The newest therapeutic approaches will be discussed in the context of the COVID-19 epidemic.

Increased knowledge of the molecular mechanisms responsible for neoplastic transformation, the biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, has allowed us to identify and apply more effective biological and immunological anticancer treatments. To date, immuno-biotherapy is a continuously evolving treatment modality and is currently integrated into the treatment algorithms of several different tumor types. Combination treatments based on immune checkpoint inhibitors (ICI) with either targeted therapy, radiotherapy or standard chemotherapy have recently been introduced in clinical practice. Rationale, *pro and contra*, and the identification of a specific subset of patients who could benefit from these approaches will be discussed.

This conference explores topics that will appeal to clinicians, as well as to, basic, translational, and clinical scientists ranging from academia to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, and provide the audience with a broad overview of the most recent achievements in biological and immunological cancer therapy.

Lastly, a wide spectrum of evolving topics in cancer research such as epigenetic drugs and CART cells will be analyzed in view of their introduction in the clinical setting.

## SCIENTIFIC RESPONSIBLES

**MICHELE DEL VECCHIO**  
**MASSIMO DI NICOLA**

Fondazione IRCCS Istituto Nazionale dei Tumori  
Via Giacomo Venezian, 1 - 20133 Milano

## SCIENTIFIC COMMITTEE

**GIOVANNI APOLONE** (Milan, Italy)  
**FILIPPO DE BRAUD** (Milan, Italy)  
**MICHELE DEL VECCHIO** (Milan, Italy)  
**MASSIMO DI NICOLA** (Milan, Italy)  
**GIANPIETRO DOTTI** (Chapel Hill, USA)  
**SOLDANO FERRONE** (Boston, USA)  
**JOHN HISCOTT** (Rome, Italy)

## FACULTY

### ANDREA ANICHINI

Responsabile di Struttura Semplice Dipartimentale "Immunobiologia dei Tumori Umani",  
Dipartimento di Oncologia Sperimentale e Medicina Molecolare, Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy)

### GIOVANNI APOLONE

Direttore Scientifico, Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy)

### FILIPPO DE BRAUD

Direttore Dipartimento di Oncologia Medica ed Ematologia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano  
Direttore Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Milano (Milan, Italy)

### MICHELE DEL VECCHIO

Responsabile S.S. Oncologia Medica Melanomi, Dipartimento di Oncologia Medica ed Ematologia  
Fondazione IRCCS Istituto Nazionale Tumori (Milan, Italy)

### PAOLO DELLABONA

Direttore Divisione di Immunologia, Trapianti e Malattie Infettive, IRCCS Ospedale San Raffaele (Milan, Italy)

### MASSIMO DI NICOLA

Responsabile S.S. Immunoterapia Clinica dei Tumori e Terapie Innovative, Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy)

### GIAMPIETRO DOTTI

Professor of Microbiology and Immunology with tenure, Director of the UNC Lineberger Immunotherapy Program  
University of North Carolina (Chapel Hill, NC, USA)

### SOLDANO FERRONE

Professor in Residence, Surgery, Harvard Medical School, Immunologist, Surgery, Massachusetts General Hospital

## FACULTY

### LUCA GATTINONI

Full professor, Chair for Functional Immune Cell Modulation,  
Regensburg Center for Interventional Immunology and University of Regensburg, Germany (Regensburg, Germany)

### CHIARA GORRINI

Senior Staff Scientist of Cancer Therapeutic Unit, Institute of Cancer Research (London (UK)  
Affiliated Scientist, Princess Margaret Cancer Center di UHN (Toronto, Canada)

### AXEL HAUSCHILD

Professor of Dermatology, Head of Dermato-Oncology and the Clinical Trial Center on Skin Cancer, Department of Dermatology,  
University Hospital Schleswig-Holstein (Kiel, Germany)

### JOHN HISCOTT

Direttore Laboratorio Pasteur, Istituto Pasteur-Fondazione Cenci Bolognetti (Rome, Italy)

### MARIA TERESA LANDI

Associate Professor, Department of Epidemiology, Bloomberg School of Public Health, The Johns Hopkins University (Baltimore, USA)

### ALBERTO MANTOVANI

Direttore Scientifico, Istituto Clinico Humanitas (Rozzano, MI, Italy)

### MASSIMO MASSAIA

Professore Associato di Ematologia del Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università degli Studi di Torino  
(Turin, Italy)

### MICHAEL NISHIMURA


Professor and Vice Chair for Surgery Research, Loyola University Chicago Stritch School of Medicine (Chicago, USA)

### JEFFREY WEBER


Deputy Director and Professor of Oncology, De'partment of Medicine at NYU Grossman School of Medicine, Laura and Isaac Perlmutter  
Cancer Center (New York, USA)

## UNDER THE PATRONAGE OF



 **Fondazione IRCCS**  
Istituto Nazionale dei Tumori

Sistema Socio Sanitario

 **Regione**  
Lombardia

Qui è nata l'Oncologia Italiana

## Thursday, 21 January 2021 · Scientific Program · Afternoon

- 14.50-14.55 Welcome remarks of Scientific Director - **G. Apolone** (Milan, Italy)
- 14.55-15.00 Introduction - **M. Di Nicola** (Milan, Italy)
- 15.00-15.30 Innate Immunity and Inflammation: from cancer to COVID-19 - **A. Mantovani** (Milan, Italy)

### **I SESSION: PRECLINICAL EVIDENCES AND NEW TARGETS**

Chairmen: **F. de Braud** (Milan, Italy), **S. Ferrone** (Boston, USA)

- 15.30-16.00 Therapeutic implications of redox metabolism in breast cancer - **C. Gorrini** (Toronto, Canada)
- 16.00-16.10 Discussion
- 16.10-16.40 Role of iNKT in adoptive T cell therapy - **P. Dellabona** (Milan, Italy)
- 16.40-16.50 Discussion
- 16.50-17.20 T Cell Receptor Gene Modified T cells for the Immunotherapy of Cancer - **M. Nishimura** (Chicago, USA)
- 17.20-17.30 Discussion
- 17.30-18.00 Mutational signatures and cancer treatment - **M.T. Landi** (Bethesda, USA)
- 18.00-18.10 Discussion

### **KEYNOTE LECTURE**

- 18.10-18.40 Adjuvant setting in Melanoma: it is time to start immunotherapy earlier - **J. Weber** (New York, USA)  
Presented by **M. Del Vecchio** (Milan, Italy)

## Friday, 22 January 2021 · Scientific Program · Afternoon

### II SESSION: CLINICAL TRANSLATION

Chairmen: **J. Hiscott** (Rome, Italy), **M. Massaia** (Cuneo, Italy)

- 15.30-16.00 Synergistic activity of targeted and immunotherapy: new paradigms - **A. Hauschild** (Kiel, Germany)  
16.00-16.10 Discussion
- 16.10-16.40 CART cells in solid tumors: preliminary clinical data - **G. Dotti** (Chapel Hill, USA)  
16.40-16.50 Discussion
- 16.50-17.20 Immune monitoring of patients treated with ICI - **A. Anichini** (Milan, Italy)  
17.20-17.30 Discussion
- 17.30-18.00 CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies  
**L. Gattinoni** (Regensburg, Germany)
- 18.00-18.10 Discussion
- 18.10-18.25 AWARD FOR THE BEST ABSTRACT  
"Generation of ALK CAR-T Cells for Neuroblastoma Therapy"  
**Elisa Bergaggio** (Milan, Italy)
- 18.25-18.30 Conclusions - **M. Del Vecchio** (Milan, Italy)



# GENERAL INFORMATIONS

## Date

Thursday, 21 January 2021 from 14.50 to 18.40

Friday, 22 January 2021 from 15.30 to 18.30

## Registration instructions

Registration is free and can be made on-line at

<https://milancongress.nadirex.org>

The Congress is not by direct invitation of the Sponsor.

## Official language

English

## CME Provider Nr. 265

## Organizing Secretariat



Nadirex International Srl

Via Riviera 39 · 27100 Pavia

Tel. +39.0382.525714/35 - Fax +39.0382.525736

[gloria.molla@nadirex.com](mailto:gloria.molla@nadirex.com)

[www.nadirex.com](http://www.nadirex.com)

## Best Abstract Award

(an educational grant of € 500.00)

having as its first author a Researcher  
< of 35 years

Abstracts will be reviewed by the Scientific Committee and may be selected for oral presentation. The presentation of accepted oral communications is subject to the registration of the Presenting Author. Total abstract length should be of 300 words maximum (references and figures excluded) and should be submitted in English.

Send it by January 18, 2021 to:  
[info@nadirex.com](mailto:info@nadirex.com)

## GENERAL INFORMATIONS

**Id ECM: 265-308562**

- **Learning hours:** 6
- **Educational goal:** Nr. 2 - Guidelines - Protocols - Procedures
- **CME credits:** Nr. 9
- **Addresses of the Congress**

The Congress is addressed to the following figures:

- Physician (Disciplines: Hematology, Infectious Diseases, Oncology, Internal Medicine, Transfusional Medicine)
- Biologist
- Biomedical Laboratory Technician
- Pharmacist (Discipline: Hospital Pharmacy)
- **Participants:** 100
- **RL (Remote Learning) product type:** Live courses on dedicated multimedia platform (Virtual Classroom, Webinar) - Synchronous RL
- **Participant Resources Required:** email address (for registration), recent and updated web browser, Internet connection, devices to enable use of learning contents (pc, smartphone or tablet) with speakers (or earphones), microphone (only if the course calls for verbal interaction between teachers and participants).

## GENERAL INFORMATIONS

### Learning verification method

Online multiple-choice questionnaire with double randomization. To earn ECM credits for the event you must:

- attend 90% of the teaching activities
- give correct answers to at least 75% of the questions on the questionnaire (a maximum of five attempts to pass the test are allowed, subject to repetition of content activities for each attempt);
- fill out the "RL evaluation form" and the "quality and learning needs questionnaire" (not mandatory)

Attention: the questionnaire will be online for only 3 (three) days after the event has concluded.

### Guidelines for Speakers and Chairmen

The Zoom room will be opened only for speakers and chairmen at:

21 January: 02.00 p.m. - 22 January: 03.00 p.m.

(For participants room opens at the beginning time of the Congress)

The Official Language for the presentation of speakers is: English

The Official Language for the slides of the speakers is: English

The Official Language for chairmen is: English

Nadirex International assumes all responsibility for the contents, quality, and ethical correctness of this ECM activity.

**WITH THE UNRESTRICTED EDUCATIONAL GRANTS OF:**

